Mint Sirisawad

3.1k total citations · 1 hit paper
38 papers, 2.4k citations indexed

About

Mint Sirisawad is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Mint Sirisawad has authored 38 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 12 papers in Genetics and 11 papers in Oncology. Recurrent topics in Mint Sirisawad's work include Histone Deacetylase Inhibitors Research (15 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Protein Degradation and Inhibitors (10 papers). Mint Sirisawad is often cited by papers focused on Histone Deacetylase Inhibitors Research (15 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Protein Degradation and Inhibitors (10 papers). Mint Sirisawad collaborates with scholars based in United States, China and Belgium. Mint Sirisawad's co-authors include Joseph J. Buggy, Erik Verner, Richard A. Miller, Betty Chang, David Loury, Lee Honigberg, Ashley M. Smith, Douglas H. Thamm, Zhengying Pan and Sriram Balasubramanian and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Mint Sirisawad

38 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

2010 1.2k citations Lee Honigberg, Ashley M. Smith et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mint Sirisawad United States	17	1.3k	956	767	695	416	38	2.4k
Erik Verner United States	18	1.3k 1.0×	899 0.9×	593 0.8×	545 0.8×	391 0.9×	30	2.5k
Kumudha Balakrishnan United States	26	1.2k 0.9×	1.5k 1.6×	893 1.2×	484 0.7×	684 1.6×	52	2.8k
Zhengying Pan China	21	1.3k 1.0×	1.4k 1.5×	840 1.1×	702 1.0×	590 1.4×	42	3.0k
Markus Warmuth United States	27	1.7k 1.4×	885 0.9×	412 0.5×	930 1.3×	288 0.7×	48	3.1k
Jeffrey J. Jones United States	19	814 0.7×	1.1k 1.1×	746 1.0×	309 0.4×	456 1.1×	32	1.9k
Victor Sandor United States	20	2.0k 1.6×	492 0.5×	431 0.6×	1.7k 2.4×	344 0.8×	35	3.2k
Sari H. Enschede United States	19	2.1k 1.7×	1.7k 1.8×	1.3k 1.6×	1.2k 1.7×	717 1.7×	46	4.0k
Juerg Schwaller Switzerland	33	2.1k 1.6×	569 0.6×	844 1.1×	1.2k 1.7×	754 1.8×	66	3.8k
Evelyn McKeegan United States	19	1.3k 1.1×	355 0.4×	263 0.3×	771 1.1×	238 0.6×	42	2.1k
Kami J. Maddocks United States	30	813 0.6×	1.8k 1.9×	2.1k 2.7×	1.5k 2.2×	893 2.1×	197	3.7k

Countries citing papers authored by Mint Sirisawad

Since Specialization

Citations

This map shows the geographic impact of Mint Sirisawad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mint Sirisawad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mint Sirisawad more than expected).

Fields of papers citing papers by Mint Sirisawad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mint Sirisawad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mint Sirisawad. The network helps show where Mint Sirisawad may publish in the future.

Co-authorship network of co-authors of Mint Sirisawad

This figure shows the co-authorship network connecting the top 25 collaborators of Mint Sirisawad. A scholar is included among the top collaborators of Mint Sirisawad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mint Sirisawad. Mint Sirisawad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuo, Hsu-Ping, Scott A. Ezell, Karl J. Schweighofer, et al.. (2017). Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Molecular Cancer Therapeutics. 16(7). 1246–1256. 45 indexed citations

Kuo, Hsu-Ping, et al.. (2016). Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas. Blood. 128(22). 4140–4140. 2 indexed citations

Evens, Andrew M., Sriram Balasubramanian, Julie M. Vose, et al.. (2015). A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clinical Cancer Research. 22(5). 1059–1066. 73 indexed citations

Kuo, Hsu-Ping, Karl J. Schweighofer, Leo W.K. Cheung, et al.. (2015). The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma. Blood. 126(23). 699–699. 39 indexed citations

Xue, Ling, Mutiah Apatira, Mint Sirisawad, & Betty Chang. (2015). Abstract 1742: Ibrutinib plus proteasome or MALT1 inhibitors overcome resistance to BCR antagonists in CARD11 mutant-expressing B-lymphoma cells. Cancer Research. 75(15_Supplement). 1742–1742. 3 indexed citations

Choy, Edwin, Yael Flamand, Sriram Balasubramanian, et al.. (2014). Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 121(8). 1223–1230. 53 indexed citations

Choy, Edwin, Sriram Balasubramanian, James E. Butrynski, et al.. (2013). Abstract LB-167: Phase I dose escalation study of abexinostat and doxorubicin in patients with metastatic sarcomas.. Cancer Research. 73(8_Supplement). LB–167. 1 indexed citations

Balasubramanian, Sriram, et al.. (2011). The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways. Blood. 118(21). 4969–4969. 2 indexed citations

Bhalla, Savita, Sriram Balasubramanian, Kevin A. David, et al.. (2009). PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells. Clinical Cancer Research. 15(10). 3354–3365. 82 indexed citations

10.

Pollyea, Daniel A., Sonali M. Smith, Nathan Fowler, et al.. (2009). A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.. Blood. 114(22). 3713–3713. 8 indexed citations

11.

Balasubramanian, Sriram, Jason Ramos, Weigang Luo, et al.. (2008). A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 22(5). 1026–1034. 363 indexed citations

12.

Balasubramanian, Sriram, et al.. (2008). The Histone Deacetylase-8 (HDAC8) Selective Inhibitor PCI-34051 Decreases Interleukin-1 Beta Secretion in Vitro and Reduces Inflammation in Vivo. Blood. 112(11). 2581–2581. 5 indexed citations

13.

Wang, Zhong, Toshihisa Mizuno, Cecilia Cortez, et al.. (2006). New polyethyleneglycol-functionalized texaphyrins: synthesis and in vitro biological studies. Dalton Transactions. 1934–1934. 50 indexed citations

14.

Evans, John P., Fengyun Xu, Mint Sirisawad, et al.. (2006). Motexafin Gadolinium-Induced Cell Death Correlates with Heme oxygenase-1 Expression and Inhibition of P450 Reductase-Dependent Activities. Molecular Pharmacology. 71(1). 193–200. 13 indexed citations

15.

Zhu, Zhiyi, Jason Ramos, Kerstin Maria Kampa-Schittenhelm, et al.. (2005). Control of ASPP2/53BP2L Protein Levels by Proteasomal Degradation Modulates p53 Apoptotic Function. Journal of Biological Chemistry. 280(41). 34473–34480. 26 indexed citations

16.

Chen, J., Jason Ramos, Mint Sirisawad, Richard A. Miller, & Louie Naumovski. (2005). Motexafin gadolinium induces mitochondriallymediated caspase-dependent apoptosis. APOPTOSIS. 10(5). 1131–1142. 19 indexed citations

17.

Chen, Jun, Jason Ramos, Mint Sirisawad, Richard A. Miller, & Louie Naumovski. (2005). Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines: Role of Elevated Intracellular Calcium.. Blood. 106(11). 4829–4829. 1 indexed citations

18.

Naumovski, Louie, Jason Ramos, Mint Sirisawad, et al.. (2005). Sapphyrins induce apoptosis in hematopoietic tumor–derived cell lines and show in vivo antitumor activity. Molecular Cancer Therapeutics. 4(6). 968–976. 35 indexed citations

19.

Naumovski, Louie, Nancy D. Bone, Mint Sirisawad, et al.. (2004). Motexafin Gadolinium, a Redox Mediator, Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells and Is Additive or Synergistic with Fludarabine.. Blood. 104(11). 4799–4799. 1 indexed citations

20.

Chen, Jun, Jason Ramos, Mint Sirisawad, Richard A. Miller, & Louie Naumovski. (2004). Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines.. Blood. 104(11). 2296–2296. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact